Harry W Herr
Overview
Explore the profile of Harry W Herr including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
226
Citations
5272
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Flaig T, Spiess P, Abern M, Agarwal N, Bangs R, Buyyounouski M, et al.
J Natl Compr Canc Netw
. 2024 May;
22(4):216-225.
PMID: 38754471
Bladder cancer, the sixth most common cancer in the United States, is most commonly of the urothelial carcinoma histologic subtype. The clinical spectrum of bladder cancer is divided into 3...
2.
Lenis A, Whiting K, Ravichandran V, Tallman J, Alam S, Chu C, et al.
JCO Precis Oncol
. 2024 May;
8:e2300274.
PMID: 38691813
Purpose: Patients with residual invasive bladder cancer after neoadjuvant chemotherapy (NAC) and radical cystectomy have a poor prognosis. Data on adjuvant therapy for these patients are conflicting. We sought to...
3.
Katims A, Tallman J, Vertosick E, Porwal S, Dalbagni G, Cha E, et al.
JAMA Oncol
. 2024 Feb;
10(4):522-525.
PMID: 38358761
Importance: With the ongoing bacillus Calmette-Guèrin (BCG) shortage, alternate therapeutic options for patients with high-risk non-muscle-invasive bladder cancer (NMIBC) are needed. Objective: To report the 5-year outcomes of a cohort...
4.
Pietzak E, Herr H
NEJM Evid
. 2024 Feb;
2(1):EVIDe2200264.
PMID: 38320108
For more than 40 years, intravesical Bacillus Calmette-Guérin (BCG) has remained the most effective treatment for non-muscle-invasive bladder cancer (NMIBC); however, tumor recurrence and progression are common, especially for those...
5.
Katims A, Gaffney C, Firouzi S, Yip W, Aulitzky A, Pietzak E, et al.
Urol Oncol
. 2023 Aug;
41(10):433.e19-433.e24.
PMID: 37640571
Background: There is limited ability to accurately diagnose and clinically stage patients with upper tract urothelial carcinoma (UTUC). The most easily available and widely used urinary biomarker is urine cytology,...
6.
Clements M, Beech B, Atkinson T, Dalbagni G, Li Y, Vickers A, et al.
J Urol
. 2023 Jun;
210(3):408.
PMID: 37317778
No abstract available.
7.
Clements M, Beech B, Atkinson T, Dalbagni G, Li Y, Vickers A, et al.
J Urol
. 2023 Mar;
209(5):910.
PMID: 36876406
No abstract available.
8.
Clements M, Beech B, Atkinson T, Dalbagni G, Li Y, Vickers A, et al.
J Urol
. 2023 Feb;
209(5):901-910.
PMID: 36724053
Purpose: We compare health-related quality of life using a broad range of validated measures in patients randomized to robotic-assisted radical cystectomy vs open radical cystectomy. Methods: We retrospectively analyzed patients...
9.
Coleman J, Yip W, Wong N, Sjoberg D, Bochner B, Dalbagni G, et al.
J Clin Oncol
. 2023 Jan;
41(8):1618-1625.
PMID: 36603175
Purpose: Neoadjuvant chemotherapy (NAC) has proven survival benefits for patients with invasive urothelial carcinoma of the bladder, yet its role for upper tract urothelial carcinoma (UTUC) remains undefined. We conducted...
10.
Mano R, Hoeh B, DiNatale R, Sanchez A, Benfante N, Reznik E, et al.
Bladder Cancer
. 2022 Oct;
8(3):291-301.
PMID: 36277327
Background: Mucosal melanoma involving the urethra is a rare disease with distinct clinical and molecular characteristics and poor outcomes. Our current knowledge is limited by the small number of reports...